U.S. Markets open in 4 hrs 13 mins
  • S&P Futures

    4,171.25
    +13.50 (+0.32%)
     
  • Dow Futures

    34,333.00
    +77.00 (+0.22%)
     
  • Nasdaq Futures

    13,406.00
    +102.50 (+0.77%)
     
  • Russell 2000 Futures

    2,233.60
    +8.10 (+0.36%)
     
  • Crude Oil

    66.68
    +0.41 (+0.62%)
     
  • Gold

    1,870.00
    +2.40 (+0.13%)
     
  • Silver

    28.68
    +0.42 (+1.49%)
     
  • EUR/USD

    1.2220
    +0.0064 (+0.5255%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.29
    +0.48 (+2.55%)
     
  • GBP/USD

    1.4215
    +0.0078 (+0.5487%)
     
  • USD/JPY

    108.8800
    -0.3200 (-0.2930%)
     
  • BTC-USD

    44,884.24
    -105.93 (-0.24%)
     
  • CMC Crypto 200

    1,247.56
    +49.64 (+4.14%)
     
  • FTSE 100

    7,055.08
    +22.23 (+0.32%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

Price Over Earnings Overview: Canopy Growth

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Looking into the current session, Canopy Growth Inc. (NYSE:CGC) shares are trading at $16.03, after a 1.01% increase. Moreover, over the past month, the stock went up by 6.58%, but in the past year, decreased by 64.37%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.

The stock is currently higher from its 52 week low by 78.11%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with specialty & generic drug manufacturers stocks, and capitalize on the lower share price observed over the year.

The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company’s current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.

Most often, an industry will prevail in a particular phase of a business cycle, than other industries.

Canopy Growth has a lower P/E than the aggregate P/E of 32.85 of the specialty & generic drug manufacturers industry. Ideally, one might believe that they might perform worse than its peers, but it’s also probable that the stock is undervalued.

P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors can become unable to attain key insights from trailing earnings.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.